BG
Bellevue Group’s Celldex Therapeutics CLDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $67.3M | Buy |
3,307,569
+235,954
| +8% | +$4.8M | 1.48% | 20 |
|
|
2025
Q1 | $55.7M | Hold |
3,071,615
| – | – | 1.25% | 20 |
|
|
2024
Q4 | $77.6M | Hold |
3,071,615
| – | – | 1.49% | 20 |
|
|
2024
Q3 | $104M | Buy |
3,071,615
+100,000
| +3% | +$3.4M | 1.69% | 16 |
|
|
2024
Q2 | $110M | Buy |
2,971,615
+175,000
| +6% | +$6.48M | 1.79% | 17 |
|
|
2024
Q1 | $117M | Buy |
2,796,615
+380,319
| +16% | +$16M | 1.79% | 16 |
|
|
2023
Q4 | $95.8M | Buy |
2,416,296
+516,296
| +27% | +$20.5M | 1.47% | 17 |
|
|
2023
Q3 | $52.3M | Buy |
1,900,000
+100,000
| +6% | +$2.75M | 0.84% | 29 |
|
|
2023
Q2 | $61.1M | Hold |
1,800,000
| – | – | 0.87% | 33 |
|
|
2023
Q1 | $64.8M | Hold |
1,800,000
| – | – | 0.94% | 37 |
|
|
2022
Q4 | $80.2M | Hold |
1,800,000
| – | – | 1.06% | 27 |
|
|
2022
Q3 | $50.6M | Buy |
1,800,000
+875,000
| +95% | +$24.6M | 0.73% | 44 |
|
|
2022
Q2 | $24.9M | Buy |
+925,000
| New | +$24.9M | 0.35% | 77 |
|
|
2017
Q4 | – | Sell |
-160,000
| Closed | -$458K | – | 135 |
|
|
2017
Q3 | $458K | Hold |
160,000
| – | – | 0.05% | 126 |
|
|
2017
Q2 | $395K | Hold |
160,000
| – | – | 0.05% | 128 |
|
|
2017
Q1 | $578K | Hold |
160,000
| – | – | 0.08% | 119 |
|
|
2016
Q4 | $566K | Hold |
160,000
| – | – | 0.12% | 106 |
|
|
2016
Q3 | $646K | Hold |
160,000
| – | – | 0.12% | 112 |
|
|
2016
Q2 | $702K | Hold |
160,000
| – | – | 0.13% | 105 |
|
|
2016
Q1 | $605K | Buy |
+160,000
| New | +$605K | 0.11% | 108 |
|